



Company Announcement

Nykode Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Oslo, Norway, September 11, 2023 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that its Chief Executive Officer, Michael Engsig and Chief Business Officer and Co-founder Agnete Fredriksen, will present and host 1x1 meetings at the H.C. Wainwright 25th Annual Global Investment Conference in New York on Monday, September 11, 2023, at 7:00 a.m. ET / 1.00 p.m. CET.

To schedule a one-on-one meeting with the Company, please contact meetings@hcwco.com at H.C. Wainwright.

The presentation slides will be available in the Investors section of the Company's website at <https://nykode.com/investors/financial-reports-and-presentations/>.

About Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for the treatment of cancer, infectious diseases and autoimmune diseases. Nykode's modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which have been shown to induce broad, strong and long-lasting antigen specific immune responses which correlates with clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus (HPV)-16 induced malignancies which demonstrated positive safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of the Roche Group.

The Company's partnerships include Genentech within oncology and a multi-target collaboration with Regeneron within oncology and infectious diseases.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics may be found at <http://www.nykode.com>.



Contact for Nykode Therapeutics ASA:

Alexandra Deschner, Head of IR
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA

Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway